GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Luminex Corp (NAS:LMNX) » Definitions » Interest Coverage

Luminex (Luminex) Interest Coverage : 6.27 (As of Mar. 2021)


View and export this data going back to 2000. Start your Free Trial

What is Luminex Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Luminex's Operating Income for the three months ended in Mar. 2021 was $13.5 Mil. Luminex's Interest Expense for the three months ended in Mar. 2021 was $-2.1 Mil. Luminex's interest coverage for the quarter that ended in Mar. 2021 was 6.27. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Luminex's Interest Coverage or its related term are showing as below:

LMNX' s Interest Coverage Range Over the Past 10 Years
Min: 3.56   Med: 5003.17   Max: No Debt
Current: 3.91


LMNX's Interest Coverage is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 19.77 vs LMNX: 3.91

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Luminex Interest Coverage Historical Data

The historical data trend for Luminex's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Luminex Interest Coverage Chart

Luminex Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Interest Coverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only No Debt No Debt No Debt N/A 3.56

Luminex Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A 7.88 2.56 2.09 6.27

Competitive Comparison of Luminex's Interest Coverage

For the Medical Instruments & Supplies subindustry, Luminex's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Luminex's Interest Coverage Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Luminex's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Luminex's Interest Coverage falls into.



Luminex Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Luminex's Interest Coverage for the fiscal year that ended in Dec. 2020 is calculated as

Here, for the fiscal year that ended in Dec. 2020, Luminex's Interest Expense was $-11.9 Mil. Its Operating Income was $42.4 Mil. And its Long-Term Debt & Capital Lease Obligation was $216.5 Mil.

Interest Coverage=-1* Operating Income (A: Dec. 2020 )/Interest Expense (A: Dec. 2020 )
=-1*42.443/-11.912
=3.56

Luminex's Interest Coverage for the quarter that ended in Mar. 2021 is calculated as

Here, for the three months ended in Mar. 2021, Luminex's Interest Expense was $-2.1 Mil. Its Operating Income was $13.5 Mil. And its Long-Term Debt & Capital Lease Obligation was $269.6 Mil.

Interest Coverage=-1* Operating Income (Q: Mar. 2021 )/Interest Expense (Q: Mar. 2021 )
=-1*13.459/-2.147
=6.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Luminex  (NAS:LMNX) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Luminex Interest Coverage Related Terms

Thank you for viewing the detailed overview of Luminex's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Luminex (Luminex) Business Description

Traded in Other Exchanges
N/A
Address
12212 Technology Boulevard, Suite 130, Austin, TX, USA, 78727
Luminex Corp develops, manufactures, and sells proprietary biological testing technologies and products to testing laboratories. It primarily serves the life sciences industries by selling products used by laboratory professionals and clinical laboratories in performing diagnostics, drug research and discovery, and clinical tests on patients. Luminex's market segments mainly include Infectious disease, Personalized medicine, and Human genetics. It offers various solutions in diverse markets, including clinical diagnostics, pharmaceutical drug discovery, biomedical research, genomic and proteomic research, and food safety. The vast majority of the company's revenue is earned in the United States. The products offered are xMAP Products, ARIES Products and VERIGENE Products, among others.
Executives
Harriss T Currie officer: SVP, Finance & CFO 12212 TECHNOLOGY BOULEVARD AUSTIN TX 78727
Todd C. Bennett officer: SVP, Global Sales & Cust Ops 12212 TECHNOLOGY BLVD. AUSTIN TX 78727
Stephen L. Eck director 12212 TECHNOLOGY BLVD., AUSTIN TX 78727
Edward A Ogunro director
Eric Shapiro officer: SR VP, GLOBAL MARKETING 12212 TECHNOLOGY BLVD. AUSTIN TX 78727
Nachum Shamir director, officer: President & CEO 12212 TECHNOLOGY BLVD, AUSTIN TX 78727
Rew Richard W. Ii officer: SVP, Gen Counsel & Corp Secy 7000 WEST WILLIAM CANNON, BUILDING ONE, AUSTIN TX 78735
Nancy Fairchild officer: SVP, Human Resources 12212 TECHNOLOGY BLVD. AUSTIN TX 78727
G Walter Lowenbaum director C/O 3D SYSTEMS CORPORATION, 333 THREE D SYSTEMS CIRCLE, ROCK HILL SC 29730
Randall Myers officer: SVP, Global Mfg and Quality 12212 TECHNOLOGY BOULEVARD AUSTIN TX 78727
Charles J. Collins officer: SR VP, R&D - US 12212 TECHNOLOGY BLVD. AUSTIN TX 78727
Dijuana K Lewis director 120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204
Jim D Kever director C/O 3D SYSTEMS, 26081 AVENUE HALL, VALENCIA CA 91355
Thomas W Erickson director OMEGA HEALTHCARE INVESTORS INC, 900 VICTORS WAY STE. 350, AMM ARBER MI 48108
Kenneth A Samet director 800 KING FARM BOULEVARD, 4TH FLOOR, ROCKVILLE MD 20850